Margaret A. Horn - 11 Oct 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders, as Attorney-in-fact for Margaret Horn
Issuer symbol
RVMD
Transactions as of
11 Oct 2024
Net transactions value
-$2,312,555
Form type
4
Filing time
15 Oct 2024, 17:31:22 UTC
Previous filing
18 Sep 2024
Next filing
18 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $182,541 +44,631 +34% $4.09 176,951 11 Oct 2024 Direct F1, F2
transaction RVMD Common Stock Options Exercise $21,959 +5,369 +3% $4.09 182,320 11 Oct 2024 Direct F1, F2
transaction RVMD Common Stock Sale $2,517,055 -50,000 -27% $50.34 132,320 11 Oct 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -44,631 -100% $0.000000 0 11 Oct 2024 Common Stock 44,631 $4.09 Direct F1
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -5,369 -5.2% $0.000000 97,382 11 Oct 2024 Common Stock 5,369 $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024.
F2 Includes 77,300 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $50.00 to $50.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.